Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. XIONG Bing is a professor of Shanghai Institute of Materia Medica (SIMM), CAS. He earned the Ph.D degree in medicinal chemistry from Chinese Academy of Sciences (2001-2003), and did the postdoctoral training in structure biology at McGill University, Canada (2003-2005). Currently, his research focuses on the structure/fragment-based drug discovery in epigenetics. His group has built an integrated platform by assembling technologies in computational chemistry, structural biology and medicinal chemistry, providing innovation in lead identification and optimization. He has published more than 70 research articles in peer-review journals including Journal of Medicinal Chemistry, ChemMedChem, PLOS One, Bioorg. Med. Chem. Lett., Bioorg. Med. Chem, EJMC, Bioinformatics, BMC Bioinformatics, journal of computer information and modeling, JCC. Dr. XIONG has received a number of awards including CPA-Servier Young Investigator Awards in Medicinal Chemistry. His group has transformed several achievements to drug companies, and two drug candidates now entered into clinical trials.

Education

2000.9-2003.7 Shanghai Institute of Materia Medica, CAS Ph.D.

1997.9-2000.7 Institute of Modern Physics, CAS M.A.

1993.9-1997.7 Jiangsu Normal University B.S.

Work Experience

2005.12---present Shanghai Institute of Materia Medica, CAS

2003.10-2005.12 McGill University, Canada.

Research Directions

1.Methodology development in structure-based/fragment-based drug discovery

2.Drug development in modulating protein posttranslational modifications

3.Epigenetics chemical biology

Grants & Research Projects

1.Minstry of Science and Technology, preclinical study on BRD4 inhibitor, Project Leader, 2017.1-2020.12

2.Minstry of Science and Technology, Epigenetics drug development, Project Leader, 2014.1-2016.12

3.National Natural Science Foundation of China, KRas-PDEdelta protein-protein interaction antagonist, Project Leader, 2015.1-2018.12

Achievements

1.build an integrated structure-based/fragment-based drug discovery platform

2.discover several potential drug candidates in epigenetics and kinases

3.discover cMet inhibitor and now in clinical trials

morefold

Social Titles

morefold

Awards & Honors

1.2012 CPA-Servier Young Investigator Awards in Medicinal Chemistry

2.committee member of Shanghai Pharmaceutical Association

3.The Tech Awards of Shanghai Pharmaceutical Association

4.The Tech Awards of Chinese Pharmaceutical Association

morefold

Pubilcations

Full Publication List

Selected Publications

1.Lv K, Chen W, Chen D, Mou J, Zhang H, Fan T, Li Y, Cao D, Wang X, Chen L, Shen J, Pei D, Xiong B. Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. J Med Chem. 2020 Sep 10;63(17):9787-9802. doi: 10.1021/acs.jmedchem.0c00962.

2.Guo Z, Zhang Z, Yang H, Cao D, Xu X, Zheng X, Chen D, Wang Q, Li Y, Li J, Du Z, Wang X, Chen L, Ding J, Shen J, Geng M, Huang X, Xiong B. Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia. J Med Chem. 2019 Jun 13;62(11):5414-5433. doi: 10.1021/acs.jmedchem.9b00297.

3.Hu J, Tian CQ, Damaneh MS, Li Y, Cao D, Lv K, Yu T, Meng T, Chen D, Wang X, Chen L, Li J, Song SS, Huan XJ, Qin L, Shen J, Wang YQ, Miao ZH, Xiong B. Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors. J Med Chem. 2019 Sep 26;62(18):8642-8663. doi: 10.1021/acs.jmedchem.9b01094.

4.Wei P, Liu B, Wang R, Gao Y, Li L, Ma Y, Qian Z, Chen Y, Cheng M, Geng M, Shen J, Zhao D, Ai J, Xiong B. Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure-activity relationship, crystal structural characterization and in vivo study. Acta Pharm Sin B. 2019 Mar;9(2):351-368. doi: 10.1016/j.apsb.2018.12.008.

5.Ma Y, Sun G, Chen D, Peng X, Chen YL, Su Y, Ji Y, Liang J, Wang X, Chen L, Ding J, Xiong B, Ai J, Geng M, Shen J. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors. J Med Chem. 2015 Mar 12;58(5):2513-29. doi: 10.1021/jm502018y.

morefold